Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)

PHASE3CompletedINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

January 31, 2009

Conditions
Cystic Fibrosis
Interventions
DRUG

AZLI 75 mg two times a day (BID)/ three times a day (TID)

Trial Locations (65)

Unknown

Birmingham

Anchorage

Phoenix

Little Rock

La Jolla

Los Angeles

Oakland

Orange

Denver

Hartford

New Haven

Jacksonville

Orlando

Atlanta

Augusta

Chicago

Glenview

Maywood

Park Ridge

Indianapolis

Wichita

Shreveport

Boston

Ann Arbor

Detroit

Minneapolis

Columbia

St Louis

Las Vegas

Livingston

Morristown

Albany

Brooklyn

Buffalo

New Hyde Park

New York

Syracuse

Valhalla

Chapel Hill

Akron

Cincinnati

Columbus

Dayton

Oklahoma City

Hershey

Philadelphia

Pittsburgh

Charleston

Columbia

Houston

San Antonio

Salt Lake City

Portsmouth

Richmond

Seattle

Morgantown

Westmead

Herston

Adelaide

Prahan

Nedlands

Perth

Edmonton

London

Auckland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00128492 - Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA) | Biotech Hunter | Biotech Hunter